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On April 27-28, 1995, the National Urban Air Toxics Research Center hosted a Symposium on Air
Toxics: Biomarkers in Environmental Applications. The purpose of the symposium was to define
the current state of the art in the application of biomarkers for environmental exposures to
benzene, toluene, styrene, 1,3-butadiene, polycyclic aromatic hydrocarbons, manganese, and
chromium. Sensitive, specific, and cost-effective biomarkers of exposure, effect, and susceptibility
may greatly improve our knowledge of the human health impacts of air toxics exposures.
Presentations were made on the first day that provided state-of-the-art background for the need,
use, and ethical considerations in biomarker research and applications. In workshops held during
the symposium, a number of recommendations were made regarding the use and need for
additional research with biomarkers. In general, the sensitivity and specificity of biomarkers for
environmental exposures, need to be improved. Reliable effect and susceptibility biomarkers are
not available for these compounds. More research needs to be done to establish and evaluate
biomarkers, linked to health effects through mechanistic studies, at environmentally relevant
exposure levels. Environ Health Perspect 104(Suppl 5):851-855 (1996)
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Introduction
The Symposium on Air Toxics: Biomarkers
in Environmental Applications, held on
April 27-28, 1995, in Houston, Texas,
was the second in a series of annual sym-
posia hosted by the National Urban Air
Toxics Research Center (NUATRC) on
important issues associated with exposures
to air toxics (defined by 1990 Clean Air
Act Amendments). The topic for this year's
symposium was selected by the Center's
Scientific Advisory Panel for the purpose of
defining the current state ofthe art ofbio-
markers for selected air toxics and their use
in population studies in urban settings as
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they would contribute to NUATRC's
strategic research plan.
NUATRC's strategic plan is focused on
assessing the role ofair toxics in causing or
exacerbating respiratory and immunologi-
cal diseases as well as reproductive and neu-
rological health effects. Assessing the public
health impacts of human exposures to
ambient air toxics is complex due to several
factors. These factors include the low
atmospheric concentrations of specific air
toxics, the myriad of confounding factors
in identifying causes of morbidity and
mortality in urban populations, and the
severe analytical limitations to establishing
causal linkages between exposures and
health effects. Increased research and expe-
rience with biomarkers offer the potential
to identify any such causal linkages in a
definitive manner.
The first day ofthe symposium provided
overview information on biomarkers,
including utilization in risk assessment,
specimen banking, and ethical issues. In
addition, state-of-the-art presentations on
different types of biomarkers were given.
The focus shifted on the second day to
four classes or groups ofair toxics that were
selected for discussion within the sympo-
sium: aromatic compounds (benzene,
toluene, and styrene), a conjugated diene
(1,3-butadiene), polycyclic aromatic
hydrocarbons, and metals (chromium and
manganese). These air toxics were selected
on the basis of two criteria: a) they ranked
high on NUATRC's priority list ofair tox-
ics and appear on other priority lists (e.g.,
U.S. Environmental Protection Agency);
and b) there is published biomarker research
experience for these air toxics. In addition,
although some of the compounds are con-
sidered carcinogens/leukemogens, they also
have immunotoxic potential, addressing
the focus of the center's plan. On the sec-
ond day, formal presentations were given
in each ofthe four groups by pairs ofinves-
tigators and were followed by formation of
working groups to address specific ques-
tions in each of the four groups of air tox-
ics. These questions were designed to
identify the status of the different types of
biomarkers in each group and recommend
future research. Summaries of the working
groups follow the "Biomarker Overview."
Biomarker Overview
The use ofbiomarkers in the assessment of
environmental health has been the topic of
a number of symposia and monographs
(1-7). In broad terms, a biomarker can
be any measurement in or from biological
material that defines an exposure or
response to that exposure. Typically,
biomarkers have been classified into three
subtypes: exposure (measurement of the
parent compound, metabolite, or unique
response attributable to a compound or
group ofcompounds), effect (a quantifiable
response of an organism that can be
directly linked to exposure), and suscepti-
bility (any factor that can vary from
individual to individual that could alter
the formation or metabolism of the com-
pound or any intermediate and biological
response). Figure 1 illustrates the rela-
tionship between personal exposure and
potential human health outcome and
intervening biomarkers.
The majority ofbiomarker studies have
focused on exposure. This is important
because the absence of exposure would
preclude the need for other biomarkers.
However, this can be misleading. For envi-
ronmental exposures, it could simply reflect
the lack of assay sensitivity. Alternatively,
detection of a biomarker of exposure does
not connote effect or health outcome,
unless some prior association has been
established. The major gaps ofknowledge
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Figure 1. Relationship of biological markers to exposure and disease. Adapted from the National Research
Council (1).
occur on the right side of Figure 1. These
gaps will be best filled by concerted efforts
to link different biomarkers to exposure
and health effects, rather than by studies
that focus on only one biomarker. Large
population studies will only be feasible with
the development of cost-effective analyses.
Therefore, it may be useful to consider spec-
imen banking when appropriate. Finally,
there is the broad issue ofbiomarker valida-
tion in humans and the low levels of expo-
sures that occur in the general population.
Some biomarkers are only formed at high
exposure concentrations because ofdifferent
metabolic pathways operating at different
exposure concentrations, and controlled
human studies with most of the air toxics
are not possible. Consequently, creative
approaches need to be developed to address
these and the research needs identified by
the working groups during the symposium,
as described below.
Summary ofWorking Groups
Given today's technology, what biomarkers
are available for use in human population
studies?
Biomarkers ofExposure
Aromatics. Most ofthe biomarkers available
for human studies have been tested in
occupational or other settings where rela-
tively high levels of exposures can occur.
However, in an environmental setting,
ambient levels of these same air toxics are
lower, and some of these same biomarkers
may not be sufficiently sensitive.
Analysis of expired breath is noninva-
sive and sensitive. Limitations of this pro-
cedure include availability of equipment
for field collection and the relatively high
cost for each collection and analysis. In a
similar manner, measurements of toluene,
benzene, and styrene in blood have been
done with high precision and reliability.
The major limitations are that only two
laboratories in the world have the required
technology to do these assays and thus
the cost is high. Both ofthese biomarkers
indicate recent exposures (2 hr).
A number ofpotential metabolite assays
and adducts were discussed. Some metabo-
lites were eliminated because oflimited sen-
sitivity and specificity. Mercapturic acid in
blood and urine was recommended as a
biomarker of exposure for benzene. In addi-
tion, muconaldehyde and S-phenylcysteine
albumin adducts may be promising bio-
markers for benzene. The most promising
biomarkers for styrene exposure include
mandelic and phenylglycoxilic acids in
urine and styrene-hemoglobin or albumin
adducts in blood.
1,3-Butadiene. Currently useful
biomarkers of exposure are those based on
biological matrices. The presence ofmetab-
olites in urine, specifically of 1,2-dihy-
droxy-4-(N-acetylcysteinyl-S)butane has
been sufficiently documented to indicate
that this is likely to be a useful biomarker
of recent (up to 6-8 hr) butadiene expo-
sure. The formation ofreaction products of
butadiene metabolites with macromole-
cules is also likely to be useful. Adducts
formed by the reaction of the monoepox-
ide metabolite ofbutadiene with the N-ter-
minal valine of hemoglobin have been
characterized. The measurement of DNA
adducts ofbutadiene metabolites may also
be feasible.
As noted above, urinary metabolites
should be useful biomarkers for determin-
ing very recent (i.e., same-day) exposure to
butadiene and would be useful for docu-
menting accidental overexposures. Single
samples could be useful for cross-sectional
screening of populations for exposure,
while 24-hr collections would be more
appropriate for assessment of individual
exposures. Lymphocyte DNA and protein
(e.g., albumin) adduct levels would pro-
vide a more useful assessment of average
exposure over a period ofdays orweeks.
Assessments ofbutadiene or metabolites
in exhaled breath or levels ofbutadiene or
its metabolites in blood will probably not
prove useful as a tool for biomonitoring.
This is because of the poor solubility of
butadiene in blood, which results in rapid
exhalation ofbutadiene following termina-
tion of exposure. Similarly, blood levels of
butadiene are expected to be low because of
its rapid exhalation and rapid metabolism.
Polycyclic Aromatic Hydrocarbons.
Internal dose markers are available to
monitor polyaromatic hydrocarbon (PAH)
metabolites in urine. These markers are
specific for the compounds they measure,
but in many cases the compound measured
is not carcinogenic and therefore not
related to risk. Measurement of 1-hydroxy-
pyrene has been validated in many expo-
sure situations and is currently the internal
dose marker ofchoice. Because 1-hydroxy-
pyrene is a noncarcinogenic metabolite, it
makes risk assessment, with cancer as an
end point, problematic. However, numer-
ous studies have shown a good correlation
between total PAHs, carcinogenic PAHs
and 1-hydroxypyrene in urine. Methods
are being developed to measure metabolites
of benzo[a]pyrene and other carcinogenic
PAHs although they may not provide any
advantages over 1-hydroxypyrene measure-
ments. The current focus is on metabolites
that reflect the activating metabolism.
The measurement ofPAH-hemoglobin
adducts is currently in its infancy. Useful
techniques are available for small alkylating
carcinogens and aromatic amines, but mea-
surement ofPAH-hemoglobin adducts has
been more difficult.
Metals. The best biomarkers ofexposure
for metals are determinations ofthe metals
themselves. However, two factors need to
be considered. First, many metals are essen-
tial in the diet, in fact both chromium and
manganese are essential and dietary defi-
ciencies should be treated. Therefore, pres-
ence ofthe metal should not be considered
an adverse human health risk, but rather
amounts above a certain value (as yet
undetermined) would be suspect. Second,
the valency of the metal is important.
Chromium can exist in multiple valence
states, with +3 and +6 being the most
important. Furthermore, the +6 state is the
form associated with an increased human
health risk, because it can cross membranes
to enter cells and exert toxicity, whereas the
+3 form is membrane impermeable.
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Therefore, metal measurements need to
take the valency into consideration. Atomic
absorption spectroscopy using a graphite
furnace is the most sensitive and practical
approach for assaying metals. Chromium
in red blood cells is the best marker for
Cr6+ exposure, but pure oxygen ashing
with a graphite furnace is essential to elimi-
nate interference of iron and other con-
founders in red blood cells. Manganese
measurements can be done in either red
blood cells or urine.
Biomarkers ofEffect
Aromatics. There are no established
biomarkers ofeffect for any ofthe aromat-
ics at environmental levels of exposure.
DNA adducts have not been investigated
and do not necessarily translate into effect
markers. Cytogenetic markers that could
be evaluated include sister chromatid
exchange, formation of micronuclei, and
HPRTmutant lymphocyte assay. The gly-
cophorin A assay may be useful for ben-
zene but may not be sensitive enough for
lower exposures. Toluene does not form
adducts and has little known health risks at
environmental levels.
1,3-Butadiene. The only effect bio-
marker that currently appears to be useful
for 1,3-butadiene is the HPRT mutant
lymphocyte assay which appears to be
responsive to chronic exposures ofabout 1
ppm. However, because various air toxics
can cause HPRT mutants, the specificity
of association of 1,3-butadiene with
HPRTmutations would be a concern in
an environmental setting where mixed
exposures occur.
Polycyclic Aromatic Hydrocarbons.
Carcinogen-DNA adduct measurements
have been made in workers and in the
general population for a variety of PAH
exposures. The data indicating that these
markers will be useful in environmentally
exposed populations are limited; most
studies have focused on groups exposed
occupationally. As these markers are used
in population studies, associations and
correlations must be made with markers of
internal dose and health effects. Measure-
ment of markers of mutation such as
HPRTand glycophorin A mutations are in
the developmental stage regarding PAH,
although initial studies have been done.
Metals. Studies on biomarkers of
chromium exposure have focused on
DNA-protein cross-links. Considerably
more studies need to be done on valida-
tion and health effects risk assessment
associated with these cross-links. Little is
known for manganese. The effect bio-
marker and clinical outcome are the same,
ie., using magnetic resonance imaging
(MRI) to establish neurological symptoms.
However, the mechanism to account for
this effect needs investigation.
Biomarkers ofSusceptibiity
Aromatics. No susceptibility biomarkers
have been established for aromatics.
A number of these biomarkers are possible
and provide avenues for future investiga-
tion. Aromatics are metabolized by cyto-
chrome P4502E1; polymorphisms may
be associated with altered susceptibility.
Similarly, the reactive metabolite is
inactivated by epoxide hydrolase, which
can be expressed in different amounts.
Polymorphic differences in DNA repair
enzymes might also be important predic-
tors ofsusceptibility.
1,3-Butadiene. No susceptibility
biomarkers for butadiene have been identi-
fied; however, there are several potential
ones that could be investigated. Butadiene
is metabolized primarily by cytochrome
P4502E1 and its epoxide metabolites are
metabolized by epoxide hydrolase and glu-
tathione S-transferase. It is therefore likely
that expression polymorphisms for these
enzymes might be associated with altered
susceptibility to butadiene toxicity. The
most likely to be important are polymor-
phisms in epoxide hydrolase. In addition,
because butadiene metabolites are geno-
toxic, polymorphic differences in DNA
repair capacity, particularly the ability to
recognize and remove alkylation products
or repair DNA cross-links, might be
important predictors ofsusceptibility.
Polycyclic Aromatic Hydrocarbons.
Although progress has been made on the
development of susceptibility markers
potentially useful in PAH exposures, given
the current level ofinformation, none is use-
ful. When possible, DNA should be stored
for the analysis ofmarkers such as P4501A1
and glutathione S-transferase. In the appli-
cation ofthese studies, the working group
emphasized that exposure and outcome
(effect) measures are critically needed to
assess the impact ofthese markers on vari-
ous levels of exposures. The current data
indicate that susceptibility markers are
extremely specific regarding compound and
dose, so information on susceptibility
obtained without these data may be difficult
to interpret, ifnot misleading.
Metals. There are no specific biomarkers
of susceptibility for metals, but anion
transport systems and DNA repair enzymes
might be under genetic control. Animal
data support the hypothesis that there is
genetic variation in susceptibility to man-
ganese, but specific mechanisms are not
certain. Nongenetic factors that may
also contribute to susceptibility are
anemia, high transferrin levels, and acute
inflammatory disease.
Recommended Biomarkers
Aromatics. Blood benzene is the most
sensitive biomarker for recent, short-term
exposure (2 hr). Breath levels also corre-
spond to recent, short-term exposure (2 hr)
and are better for subject compliance.
Mercapturic acid in urine reflects whole
body metabolism and integrates exposures
over a longer period (a few hours). Blood
protein adducts integrate exposures over a
much longer period (weeks to months).
1,3-Butadiene. Air concentrations of
butadiene should be used for routine
assessment ofexposure. Charcoal tubes and
air pumps, or passive absorbent technolo-
gies are fairly well established for this pur-
pose. For unanticipated accidental exposures
and to determine the relationships between
external exposure and internal dose, use
exposure markers. To address the relation-
ship between internal dose and effect of
dose, to investigate mechanistic issues, and
for risk assessment, use effect biomarkers.
Polycyclic Aromatic Hydrocarbons.
Assays for 1-hydroxypyrene should be incor-
porated into studies to acquire information
about the degree ofexposure to PAHs.
Metals. Protein-DNA cross-links
should be used to assess chromium expo-
sure. For manganese, the presence of the
metal in urine and red blood cells is diag-
nostic, but magnetic resonance imaging
(neurological exam) should be included for
suspect populations ofmanganese exposure.
CurrentKnowledge
Aromatics. The biomarkers of effect in
exposure to aromatics are unclear. To use
protein adducts as biomarkers, there is a
need for more sensitive and specific assays
and knowledge of the time of integration
of exposure. There is also a need for more
simultaneous measurements of different
biomarkers. On the whole, more effects
and susceptibility biomarkers are needed
(Figure 1, right side). There is insufficient
information on the mechanism by which
benzene causes leukemia. Development of
immunoassays for adduct biomarkers
would be useful.
1,3-Butadiene. The relationship
between exposure level and biological effect
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is poorly defined. More detailed studies in
which exposures are determined with more
precision will be required to address this
problem. The predictive value ofbiomark-
ers for toxicity related to butadiene is not
known. This cannot be determined unless
the human health risks of butadiene expo-
sure are identified. Studies to accomplish
this may prove to be difficult.
Appropriate target tissue-specific bio-
markers for butadiene are not available.
As the major health effects appear to be
hematopoietic cancers, target tissues would
include the bone marrow and other sites of
hematopoiesis. In addition, animal studies
implicate the lungs as possible targets. The
most practical way to address this problem
would be to conduct detailed pharmacoki-
netic studies and develop pharmacokinetic
models to assess dosimetry in humans
exposed to 1,3-butadiene.
The influence of other factors on the
response of biomarkers is not well under-
stood. Co-exposures to other workplace
chemicals and substances related to lifestyle
(e.g., smoking, diet) or medications, might
influence the response to specific bio-
markers. This problem could be addressed
with large-scale studies ofexposed popula-
tions designed to permit multivariate
analysis of the effects of factors on the
response ofbiomarkers.
Polycyclic Aromatic Hydrocarbons.
Sensitive assays for metabolites of carcino-
genic PAH need to developed. Associations
need to be developed between markers
of internal dose and later effects must be
determined.
Metals. Normal values and reference
ranges are not established for metals. In
addition there is insufficient information
on the mechanism of manganese-induced
neurological disease.
Drawbacks ofCurrentMethodology
in Conducting BiomarkerStudies
in Human Populations
Aromatics. Only two laboratories world-
wide do blood assays for aromatics. In addi-
tion, there is insufficient information from
longitudinal studies on individual variation
to predict and interpret single measure-
ments. For benzene there is much greater
inter- than intraindividual variation.
1,3-Butadiene. In addition to the
problems described above (relationship of
exposure to effect, predictive value, con-
founding factors), several additional pitfalls
exist for butadiene. The weaknesses and
hazards of any observational study design
for biomarker studies apply to butadiene.
Issues of sample size, ascertainment of
exposure, correct assignment to exposure
groups, proper selection ofend points, and
control of confounding factors are all
important. Currently available techniques
for biomonitoring are relatively complex
and expensive to perform, making them
too costly for routine use. Simpler, more
reliable, and less expensive tests need to be
developed. A final and significant pitfall to
be resolved is the manner in which the
results ofbiomarker studies are interpreted
and communicated. As more experience is
gained and the issues are resolved, the
interpretation of results will become
clearer. During the developmental phase of
biomarker use it is important to pay partic-
ular attention to the manner in which
results are interpreted and communicated
to exposed workers and the general public.
Although, it is important to be factual and
not to ignore the implications of positive
findings for future disease risk, it is also
necessary to be honest in describing the
limitations in current knowledge and the
uncertainties they create for interpretation
of results. The successful application of
biomarkers to the evaluation ofhealth risks
in butadiene-exposed workers will require
cooperation ofindustry.
Polycyclic Aromatic Hydrocarbons.
The technology and methodologies
are available using HPLC, GC, postlabel-
ing, and radioimmunoassays for monitor-
ing PAH exposure. PAHs are a mixture
and monitoring requires an integrated
approach. None of the methods currently
available can fingerprint exposure to a
specific compound.
Major problems in monitoring PAH
exposure are the cost of each assay, the
quantity ofspecimen needed, and availabil-
ity and accessibility ofdefined study popu-
lations with different levels of exposure to
be able to evaluate the dose-response rela-
tionships ofexposure and markers.
Metals. While Cr3+ is an essential
element, no amount of Cr6+ is desirable,
and all Cr6+ is converted to Cr3+ in cells.
Better markers of effect for manganese
exposure need to be developed to replace
MRI. Manganese is an essential factor in
metabolism and deficiency needs treatment.
PriorityofResearchNeeds
All groups had key research needs that
were similar:
a) develop an understanding of the
mechanistic linkage between the response
ofa biomarker, chemical exposure, and the
potential for future disease (ie., develop an
association between biomarkers and risk
assessment and etiological studies rather
than descriptive studies using a single
exposure marker);
b) characterize the behavior of specific
biomarkers, the relationships between
responses of different biomarkers and the
response ofthe biomarkers to other factors
(other chemicals, smoking, diet, etc.); and
c) develop more sensitive and specific
assays and knowledge of the time of inte-
gration ofexposure. Develop immunoassays
for adducts.
Aromatics. Biomarkers of effect, and
more biomarkers of susceptibility should
be developed for aromatics.
1,3-Butadiene. The exposure of
workers in representative workplaces in the
United States must be characterized to
determine whether current levels ofbutadi-
ene exposure produce significant responses
in exposure or effect biomarkers.
Also, we must determine whether subsets
of individuals with unusual susceptibilities
to the toxic effects ofbutadiene exist.
Polycyclic Aromatic Hydrocarbons.
Integrated studies involving a variety of
health professionals should be conducted.
Field and laboratory studies should be
undertaken not only to understand the
exposure in the population, but also the
interaction between markers of exposure,
effect, and susceptibility (e.g., PAH-
metabolites, PAH-hemoglobin and DNA
adducts, mutation, P4501A1, and glu-
tathione S-transferase). The study ofmark-
ers of susceptibility should not be a top
priority until the interrelationships of
exposure and the markers are established.
Metals. Chromium-induced protein-
DNA cross-links and association with dis-
ease (not gene specific) must be validated.
We must search for other biomarkers of
effect for manganese, define the mecha-
nism ofaction in toxicity, and define non-
genetic factors ofsusceptibility.
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